Published in J Infect Dis on January 05, 2012
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS (2014) 0.94
HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS (2014) 0.92
HIV stroke risk: evidence and implications. Ther Adv Chronic Dis (2013) 0.86
In vivo assessment of antiretroviral therapy-associated side effects. Mem Inst Oswaldo Cruz (2014) 0.75
PR Interval and sudden cardiac death in patients with HIV infection. J Infect Dis (2012) 0.75
Relationship between HIV infection, antiretroviral therapy, inflammatory markers and cerebrovascular endothelial function among adults in urban China. J Acquir Immune Defic Syndr (2016) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Why do people sue doctors? A study of patients and relatives taking legal action. Lancet (1994) 10.79
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr (2012) 10.61
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) 6.62
The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect (2008) 5.98
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Vitellogenin in Xenopus laevis is encoded in a small family of genes. Cell (1979) 4.44
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J Clin Microbiol (1996) 3.85
Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol (1994) 3.81
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med (2001) 3.55
Insertional mutagenesis of genes required for seed development in Arabidopsis thaliana. Genetics (2001) 3.49
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 3.41
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet (2014) 3.31
Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol (1992) 3.30
Use of personal medical records for research purposes. BMJ (1994) 3.29
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet (1991) 2.87
Sexual and reproductive life of women informed of their HIV seropositivity: a prospective cohort study in Burkina Faso. J Acquir Immune Defic Syndr (2001) 2.86
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med (1997) 2.84
Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res (2000) 2.82
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet (1999) 2.80
Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol (2008) 2.74
A primary genetic linkage map for human chromosome 12. Genomics (1987) 2.72
Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics (1999) 2.69
Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis (2007) 2.68
How effective is nicotine replacement therapy in helping people to stop smoking? BMJ (1994) 2.68
Late presentation of HIV infection: a consensus definition. HIV Med (2011) 2.67
The prediction of criminal and violent recidivism among mentally disordered offenders: a meta-analysis. Psychol Bull (1998) 2.60
Migration and geographic variations in blood pressure in Britain. BMJ (1990) 2.55
Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol (1993) 2.52
Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroaggregative Escherichia coli. Infect Immun (1997) 2.50
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet (1992) 2.40
Vitellogenesis and the vitellogenin gene family. Science (1981) 2.39
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Human Gene Mutation Database: towards a comprehensive central mutation database. J Med Genet (2008) 2.37
Operational issues in preventing mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire, 1998-99. Bull World Health Organ (2001) 2.33
Molecular characterization of Cryptosporidium isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. J Clin Microbiol (2000) 2.32
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.23
Laparoscopic assisted live donor nephrectomy--a comparison with the open approach. Transplantation (1997) 2.23
Cows' milk-sensitive enteropathy. Arch Dis Child (1978) 2.22
Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Arch Dermatol (1998) 2.22
Monitoring selective components of primary health care: methodology and community assessment of vaccination, diarrhoea, and malaria practices in Conakry, Guinea. ACSI-CCCD team. Bull World Health Organ (1989) 2.20
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet (1993) 2.18
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis (2011) 2.15
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA (2000) 2.12
An appraisal of the efficacy and cost effectiveness of antenatal screening for hepatitis B. J Med Screen (1997) 2.12
Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol (1998) 2.11
Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10
Implementing family-focused HIV care and treatment: the first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Côte d'Ivoire. Trop Med Int Health (2009) 2.07
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection (2011) 2.00
Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Epidemiology (1998) 2.00